Expression of mediators of renal injury in the remnant kidney of ROP mice is attenuated by cyclooxygenase-2 inhibition

Nephron Exp Nephrol. 2005;101(3):e75-85. doi: 10.1159/000086645. Epub 2005 Jun 30.

Abstract

To investigate the effects of cyclooxygenase-2 (COX-2) inhibition on renal injury of mice, ROP mice were subjected to subtotal ablation ('remnant'). A subset of the remnant group was treated with a selective COX-2 inhibitor, SC58236, in the drinking water. At 12 weeks the remnant group developed significant albuminuria (181.3 +/- 15.8 microg/24 h), which was blunted by SC58236 treatment (138.9 +/- 17.1; p < 0.05 compared to remnant). SC58236 did not alter systemic blood pressure or GFR significantly. Immunoreactive COX-2 was upregulated in remnant (1.88 +/- 0.35 fold sham, n = 8, p < 0.05), which was blunted by SC58236 (to 1.26 +/- 0.31 fold sham). Collagen IV mRNA increased significantly in remnant kidneys (2.69 +/- 0.34 fold sham, n = 8, p < 0.05), and this increase was inhibited by SC58236 treatment (to 1.84 +/- 0.32 fold control). Immunoreactive TGF-beta1, connective tissue growth factor, HGF receptor, c-Met, and fibronectin all increased in remnant (2.85 +/- 0.51, 3.83 +/- 0.55, 2.56 +/- 0.31, and 2.80 +/- 0.39 fold sham respectively, n = 4-8, p < 0.05), and SC58236 blunted the increases (to 1.45 +/- 0.34, 1.85 +/- 0.13, 1.75 +/- 0.30, and 1.60 +/- 0.32 fold sham). Immunohistochemistry indicated that the major localization for these progression factors was in the tubulointerstitium, especially in the scar area, which is in agreement with the expression of a macrophage marker, F4/80. Therefore, these results indicate that in a mouse model of subtotal renal ablation, COX-2 inhibition blocks expression of mediators of renal tubulointerstitial injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Connective Tissue Growth Factor
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Fibronectins / antagonists & inhibitors*
  • Glomerulosclerosis, Focal Segmental / genetics
  • Glomerulosclerosis, Focal Segmental / metabolism*
  • Glomerulosclerosis, Focal Segmental / pathology
  • Glomerulosclerosis, Focal Segmental / urine
  • Immediate-Early Proteins / antagonists & inhibitors*
  • Intercellular Signaling Peptides and Proteins
  • Kidney / metabolism*
  • Kidney / pathology
  • Kidney Tubules / metabolism
  • Mice
  • Mice, Inbred Strains
  • Nephrectomy
  • Proteinuria / physiopathology
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • Pyrazoles / pharmacology
  • Sulfonamides / pharmacology
  • Tissue Distribution

Substances

  • 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
  • CCN2 protein, mouse
  • Cyclooxygenase 2 Inhibitors
  • Fibronectins
  • Immediate-Early Proteins
  • Intercellular Signaling Peptides and Proteins
  • Pyrazoles
  • Sulfonamides
  • Connective Tissue Growth Factor
  • Proto-Oncogene Proteins c-met